New hope for rare vasculitis patients who failed standard therapy
NCT ID NCT07268521
First seen Jan 06, 2026 · Last updated Jun 16, 2026 · Updated 27 times
Summary
This study tests a drug called obinutuzumab in 30 adults with a rare, serious blood vessel disease (cryoglobulinemia vasculitis) that did not improve with or caused reactions to the standard treatment rituximab. The goal is to see if obinutuzumab can stop disease activity and allow patients to reduce steroid use. It is a phase 2 trial, meaning it is early but promising, and participants will be closely monitored for safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRYOGLOBULINEMIC VASCULITIS (CV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.